These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17261237)

  • 1. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2007 Jan; 23(1):207-22. PubMed ID: 17261237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2008 Feb; 24(2):515-35. PubMed ID: 18186971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).
    Schlander M
    Curr Med Res Opin; 2008 Apr; 24(4):951-66. PubMed ID: 18279581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinician perspectives on the use of National Institute for Health and Care Excellence guidelines for the process of transition in Attention Deficit Hyperactivity Disorder.
    Eke H; Janssens A; Newlove-Delgado T; Paul M; Price A; Young S; Ford T
    Child Care Health Dev; 2020 Jan; 46(1):111-120. PubMed ID: 31613391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NICE ADHD health technology assessment: a review and critique.
    Schlander M
    Child Adolesc Psychiatry Ment Health; 2008 Jan; 2(1):1. PubMed ID: 18197978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE guidance on ADHD. NICE should produce guidance on infant mental health.
    Gracias SA
    BMJ; 2008 Oct; 337():a2288. PubMed ID: 18957463
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related references in national public health, technology appraisal and clinical guidelines and guidance: documentary analysis.
    Forrest LF; Adams J; Ben-Shlomo Y; Buckner S; Payne N; Rimmer M; Salway S; Sowden S; Walters K; White M
    Age Ageing; 2017 May; 46(3):500-508. PubMed ID: 27989991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
    Towse A; Pritchard C
    Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priority setting in kidney transplantation: a qualitative study evaluating Swedish practices.
    Omar F; Tinghög G; Carlsson P; Omnell-Persson M; Welin S
    Scand J Public Health; 2013 Mar; 41(2):206-15. PubMed ID: 23287398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the impact of NICE guidance on GP prescribing.
    Wathen B; Dean T
    Br J Gen Pract; 2004 Feb; 54(499):103-7. PubMed ID: 14965388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.